Results 171 to 180 of about 78,739 (228)

Tocilizumab for severe and refractory mucous membrane pemphigoid

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1682-1691, October 2026.
Elevated IL‐6 levels identified in mucous membrane pemphigoid support IL‐6 blockade, with tocilizumab demonstrating clinical benefit in nine patients with severe and refractory mucous membrane pemphigoid. Abstract Background Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially ...
Billal Tedbirt   +20 more
wiley   +1 more source

Lessons for Immunisation Policy and Practice From the Deadly Measles Resurgence in Bangladesh

open access: yesTropical Medicine &International Health, Volume 31, Issue 10, Page 1499-1504, October 2026.
ABSTRACT Bangladesh is experiencing one of the deadliest outbreaks of measles in 2026, with at least 472 suspected child deaths and over 67,079 suspected cases as of 27 May 2026. It has happened primarily following a fall in measles vaccination coverage in 2025, largely due to the cancellation of a planned 2024 Measles–Rubella vaccination Campaign and ...
Md Masudul Haque   +6 more
wiley   +1 more source

Criteria for Control and Remission of Respiratory Allergic Disease With Allergen Immunotherapy: A Delphi Consensus. [PDF]

open access: yesClin Transl Allergy
González-Mancebo E   +11 more
europepmc   +1 more source

Diagnosis of chlamydial and gonococcal conjunctivitis: performance evaluation of a nucleic acid amplification test. [PDF]

open access: yesMicrobiol Spectr
Bédard O   +10 more
europepmc   +1 more source

GWAS of Second‐Generation Antihistamine Use: Locus Specificity and Highlighted Signalling Pathways

open access: yes
Clinical &Experimental Allergy, Volume 56, Issue 10, Page 1224-1226, October 2026.
M. Niemi   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy